<DOC>
	<DOCNO>NCT00619879</DOCNO>
	<brief_summary>The purpose study show myeloablative hematopoietic progenitor cell transplantation ( HPCT ) continue offer acceptable disease-free survival select patient require HPCT .</brief_summary>
	<brief_title>Myeloablative Hematopoietic Progenitor Cell Transplantation ( HPCT ) Pediatric Malignancies</brief_title>
	<detailed_description>Myeloablative hematopoietic progenitor cell transplantation ( HPCT ) remain standard care patient require HPCT . The purpose study evaluate morbidity mortality myeloablative HPCT Children 's Memorial Hospital . It also look determine toxicity single condition regimen consist total body irradiation ( TBI ) , etoposide ( VP-16 ) , Cyclophosphamide patient transplant eligible lymphoid malignant condition transplant eligible myeloid malignant condition receive cord blood unit , determine toxicity single condition regimen consist Busulfan Cyclophosphamide patient transplant eligible myeloid malignant condition receive cord blood unit .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Malignant Disease Chronic myleogenous leukemia chronic accelerate phase Acute lymphoblastic leukemia ( ALL ) First remission highrisk ALL ( Ph+ , ( 411 ) infant ) . Second remission ALL , short first remission ( &lt; 36 mo Dx ) . 3rd great remission ALL . Acute myelogenous leukemia ( AML ) First remission high risk acute nonlymphoblastic ( ANLL ) ( define cytogenetics ) , match sibling donor available . Initial partial remission AML ( &lt; 20 % blast bone marrow ) . AML refractory two cycle induction therapy . Second great remission AML Myelodysplastic/Myeloproliferative Disease Juvenile Myelomonocytic Leukemia ( JMML ) Myelosplastic syndrome and/or preleukemia stage Lymphoma Relapsed lymphoma residual disease appear chemosensitive nonbulky ( &lt; 5 cm large diameter ) Venous Access : Three lumens central vascular access require patient enter protocol due need dedicated line continuous infusion cyclosporine . Informed Consent : The patient and/or patient 's legally authorized guardian must acknowledge write consent become study subject obtain accordance institutional policy approve U.S. Department Health Human Services . Patient organ function requirement : Adequate renal function : Serum Creatinine &lt; ~1.5 x normal , Creatinine clearance 70 mL/min/1.73 mE2 equivalent GFR determine institutional normal range Adequate liver function : Total bilirubin &lt; 1.5 x normal ; SGOT ( AST ) SGPT ( ALT ) &lt; ~2.5 x normal Adequate cardiac function : Shortening fraction &gt; /=27 % echocardiogram Adequate pulmonary function : FEV1/FVC &gt; /=60 % pulmonary function test ; child uncooperative , evidence dysnpea rest , exercise intolerance , must pulse oximetry &gt; 94 % room air Performance status : Lansky child &lt; /= 16 year &gt; /= 60 ; Karnofsky status &gt; 16 year age &gt; /= 70 Effective Contraceptive Use : Women childbearing potential sexually active male use effective contraception study . Patients pregnant lactating Inability find suitable donor patient Patient HIVpositive Patient active Hepatitis B Disease progression relapse prior HPC infusion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Leukemia , Myelogenous , Chronic</keyword>
	<keyword>Leukemia , Lymphoblastic , Acute</keyword>
	<keyword>Leukemia , Myelogenous , Acute</keyword>
	<keyword>Myeloproliferative-Myelodysplastic Diseases</keyword>
	<keyword>Juvenile Myelomonocytic Leukemia</keyword>
	<keyword>Dysmyelopoietic Syndromes</keyword>
	<keyword>Lymphoma , Malignant</keyword>
	<keyword>Stem Cell Transplantation , Hematopoietic</keyword>
	<keyword>Allogeneic Transplantation</keyword>
	<keyword>Human Leukocyte Antigens</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Total Body Irradiation</keyword>
	<keyword>VP-16</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Graft-Versus-Host Disease</keyword>
</DOC>